Status:
RECRUITING
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
Lead Sponsor:
Kessler Foundation
Collaborating Sponsors:
Hackensack Meridian Health
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-64 years
Brief Summary
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS). Cognitive...
Detailed Description
The researchers aim is to investigate the effects of disease modifying treatments on cognitive fatigue and on specific brain areas that have been shown to underlie cognitive fatigue in individuals wit...
Eligibility Criteria
Inclusion
- Age between 18-64.
- Relapsing remitting multiple sclerosis
- Been newly prescribed a new disease modifying medication for MS (either Ocrevus or Copaxone)
- or healthy volunteer who can speak English fluently.
Exclusion
- History of head injury, stroke, seizures, or any other significant neurological event other than MS
- Flare up of MS symptoms within the past month.
- History of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder.
- Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments.
- left handed.
- Not able to have an MRI
Key Trial Info
Start Date :
May 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04448977
Start Date
May 6 2021
End Date
December 1 2024
Last Update
February 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kessler Foundation
West Orange, New Jersey, United States, 07052